
Currently out of the existing stock ratings of Adnan Butt, 52 are a BUY (86.67%), 3 are a HOLD (5%), 5 are a SELL (8.33%).
Analyst Adnan Butt, has had 68.4% of price targets met with an average potential upside of 68.88%, reached in 522 days on average. Previously, Adnan Butt worked at GUGGENHEIM, RBC.
Adnan Butt has documented 134 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 22-Feb-2019.
Analyst best performing recommendations are on NBRV (NABRIVA THERAPEUTICS AG).
The best stock recommendation documented was for NBRV (NABRIVA THERAPEUTICS AG) on 11/12/2015. The price target of $5500 was fulfilled within 35 days with a profit of $54000 (90.76%), with a performance score of 25.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Mar-2016
$85
$90
6 years 11 months 25 days ago
(26-Nov-2019)
1/5 (20%)
$1.12 (1.34%)
1338
Buy Since 28-Mar-2019
$85
$100
6 years 11 months 26 days ago
(25-Nov-2019)
1/5 (20%)
$1.25 (1.49%)
243
Buy Since 30-Nov-2017
$68
$68
6 years 11 months 26 days ago
(25-Nov-2019)
4/6 (66.67%)
$-15.75 (-18.81%)
235
Hold Since 20-Nov-2019
$59
$55
7 years ago
(20-Nov-2019)
8/9 (88.89%)
$-11.59 (-16.42%)
148
Buy Since 19-Apr-2017
$60
$55
7 years 20 days ago
(31-Oct-2019)
5/5 (100%)
$7.51 (14.31%)
205